TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20600512
Drug: 40 mcg
Normalized name: Caverject 40 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mcg HBV vaccine without GM-CSF (control)
Study: 15987669
Drug: Drug-naïve patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-naïve patients
Study: 15987669
Drug: Drug-naïve and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-naïve and treated patients
Study: 9920948
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg) plus methotrexate
Study: 9208666
Drug: Madopar treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Madopar treatment (26 amblyopia eyes)
Study: 7356903
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg cimetidine with 250 mg tetracycline tablets
Study: 7356903
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 250 mg tetracycline tablets
Study: 7356903
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg cimetidine 8 hourly for 6 days with 500 mg tetracycline as tablets
Study: 7356903
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 500 mg tetracycline as suspension
Study: 7356903
Drug: Tetracycline tablets
Normalized name: Oxytetracycline Tablets
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline tablets and suspension
Study: 26227922
Drug: Peri-articular injections
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-articular injections (PAI)
Study: 24668608
Drug: 0.05% aspartame
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% aspartame solution
Study: 24668608
Drug: 9.0% maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.0% maltodextrin solution
Study: 22928884
Drug: 30% oral
Normalized name: Lactobacillus Acidophilus/Lactobacillus Bifidus 70%-30% Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% oral glucose
Study: 15987428
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy (1 mg/day of micronized 17beta‐estradiol)
Study: 15987428
Drug: Combined estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined estrogen and progestin therapy (17beta‐estradiol and 5 mg/day of medroxyprogesterone acetate for 12 days/month)
Study: 2404204
Drug: Azathioprine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2.5 mg per kilogram of body weight per day)
Study: 31806052
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy (group A)
Study: 22000747
Drug: Neoadjuvant radiochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant radiochemotherapy with radiation doses of 50.4 Gy combined with 5-fluorouracil-based chemotherapy
Study: 12722936
Drug: 8 adjunctive
Normalized name: ANESTHETIC ADJUNCTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 adjunctive hypnosis sessions targeting accelerated wound healing
Study: 12722936
Drug: 8 adjunctive
Normalized name: ANESTHETIC ADJUNCTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 adjunctive supportive attention sessions
Study: 10802311
Drug: CS-insulin
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-insulin
Study: 1643679
Drug: meperidine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: meperidine 0.25 mg.kg‐1
Study: 1643679
Drug: meperidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: meperidine 0.5 mg.kg‐1
Study: 1643679
Drug: pancuronium 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: pancuronium 0.06 mg.kg‐1 intravenously
Study: 6426931
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg valerian (1 capsule Harmonicum Much)
Study: 6426931
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg valerian (2 capsules Harmonicum Much)
Study: 26575111
Drug: LNG-IUS +
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG-IUS + low-dose transdermal estradiol (TDE) gel (0.06% containing 0.75 mg of TDE, administered once daily for 50 days)
Study: 26575111
Drug: LNG-IUS +
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG-IUS + low-dose transdermal estradiol (TDE) gel
Study: 12814339
Drug: Calcipotriol +
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol + acitretin combination therapy
Study: 12814339
Drug: Acitretin monotherapy
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin monotherapy
Study: 8018618
Drug: Goserelin (GnRH-agonist)
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin (GnRH-agonist)
Study: 2501801
Drug: Flupenthixol dihydrochloride
Normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixol dihydrochloride (1 to 2 mg/day)
Study: 2501801
Drug: Fluvoxamine maleate
Normalized name: Fluvoxamine Maleate
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluvoxamine maleate (100 to 200 mg/day)
Study: 576832
Drug: Reproterol (Bronchospasmin)
Normalized name: reproterol
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reproterol (Bronchospasmin) - i.v. 60 and 90 mug, single peroral administration of 20 mg, long-term therapy with 60 mg in either 3 or 6 daily doses
Study: 26318552
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical stimulation of the calf muscles for 1 hour session twice daily for the first postoperative week
Study: 21788224
Drug: Pagibaximab 90
Normalized name: Pagibaximab
DrugBank: Pagibaximab (DB17786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pagibaximab 90 mg/kg
Study: 21788224
Drug: Pagibaximab 60
Normalized name: Pagibaximab
DrugBank: Pagibaximab (DB17786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pagibaximab 60 mg/kg
Study: 19470769
Drug: Chronomodulated infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronomodulated infusion of 5-fluorouracil, leucovorin, and oxaliplatin
Study: 19470769
Drug: Conventional infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional infusion of 5-fluorouracil, leucovorin, and oxaliplatin
Study: 15269349
Drug: Beta-adrenergic antagonist
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic antagonist propranolol administered at encoding
Study: 11677004
Drug: Moderate daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate daily exercise program (n=14)
Study: 11677004
Drug: No physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No physical activity beyond usual daily requirements (n=11)
Study: 1867167
Drug: 38% phosphoric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38% phosphoric acid gel for 60 seconds
Study: 1867167
Drug: 60% phosphoric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60% phosphoric acid gel with 0.5% sodium fluoride for 60 seconds
Study: 418745
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg diethylcarbamazine daily for five months
Study: 418745
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg diethylcarbamazine daily for five months
Study: 418745
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg diethylcarbamazine daily for seven weeks
Study: 26034151
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg once weekly
Study: 21594216
Drug: 10 mm
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mm long implants in augmented bone
Study: 17210593
Drug: Epoetin alfa,
Normalized name: EPOETIN ALFA,RECOMBINANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin alfa, maximum dosage >100 IU/kg/week during stabilization phase
Study: 17210593
Drug: Epoetin dosage
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin dosage
Study: 17210593
Drug: Older age,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older age, higher BMI, anaemia, ACE inhibitor/ARB use, diabetes as primary cause of kidney disease
Study: 9358616
Drug: Plasma rich
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma rich in HIV antibodies
Study: 27352493
Drug: Medication (betahistine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (betahistine mesylate)
Study: 24561488
Drug: Once-daily voglibose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily voglibose
Study: 24561488
Drug: Thrice-daily voglibose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-daily voglibose
Study: 20647773
Drug: Nimotuzumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab (200 mg/dose, once a week for six weeks) with chemoradiation
Study: 15770976
Drug: G‐SPECT in
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐SPECT in patients with GEs
Study: 11926695
Drug: Active ibuprofen
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ibuprofen 5% gel (Ibugel)
Study: 7543038
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg nalbuphine
Study: 328192
Drug: Fructose (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (1.2 g.kg‐1)
Study: 328192
Drug: Dextrose (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose (1.2 g.kg‐1)
Study: 28589334
Drug: Fixed bearing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed bearing implant
Study: 28589334
Drug: Mobile bearing
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile bearing implant
Study: 25741971
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations of PCV15
Study: 21458143
Drug: Free-hand injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free-hand injection without ultrasound guidance
Study: 19266265
Drug: Polyethyleneoxide (PEO)
Normalized name: polyethylenimine hydrochloride (20000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethyleneoxide (PEO) based heparin bonded extracorporeal circuits (ECC) + Continuous Leukocyte filtration
Study: 19266265
Drug: PEO based
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEO based heparin bonded ECC without leukofiltration
Study: 15329029
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment (antibacterials only if failed to improve after 7 days)
Study: 15329029
Drug: Empirical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical treatment (all patients initially treated with antibacterials)
Study: 15329029
Drug: Radiology-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiology-guided treatment
Study: 15329029
Drug: Treatment based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment based on specific clinical criteria
Study: 10649155
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol plus 30 microg norgestimate
Study: 10649155
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol plus 90 microg norgestimate
Study: 10649155
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol plus 180 microg norgestimate
Study: 10649155
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol daily
Study: 28660498
Drug: Degarelix 2.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degarelix 2.8 mg
Study: 22517190
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (42 mg nicotine patches)
Study: 21512399
Drug: CR2 (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR2 (0.15 g·kg creatine during 2 d wk of RT)
Study: 21512399
Drug: CR3 (0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR3 (0.10 g·kg creatine during 3 d wk of RT)
Study: 12964450
Drug: Biofeedback assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback assisted relaxation therapy (BFRT)
Study: 8712747
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antifungal agent)
Study: 1681560
Drug: BW234U (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: BW234U (two different dosage ranges)
Study: 7036288
Drug: Intraarterial chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial chemotherapy (DTIC 80 mg/m2 + 8 days prior to surgery)
Study: 7036288
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy (vinblastine 6 mg/m2, thiotepa 6 mg/m2, rufocromycine 60 microgram/m2, methotrexate 15 mg/m2 on day 1, procarbazine 30 mg/m2 for 7 days)
Study: 7036288
Drug: Chemoimmunotherapy (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoimmunotherapy (chemotherapy identical to above + DTIC 300 mg/m2 for each course + BCG every 4 weeks + C. parvum every week)
Study: 31808709
Drug: Open-label chamomile
Normalized name: Chamomile
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label chamomile extract 1500 mg daily for 8 weeks
Study: 31801593
Drug: Fire needle
Normalized name: Fire Out
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fire needle therapy (group A1)
Study: 31801593
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment (group B)
Study: 26564598
Drug: Evacetrapib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib monotherapy
Study: 26564598
Drug: Statin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin monotherapy (rosuvastatin and simvastatin)
Study: 26564598
Drug: Evacetrapib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib monotherapy and evacetrapib combined with statins
Study: 16317063
Drug: Regular +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular + NPH insulin (R+N)
Study: 15623591
Drug: Thalidomide 400
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide 400 mg daily
Study: 15623591
Drug: Prednisone 50
Normalized name: prednisone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 50 mg on alternate days
Study: 12194618
Drug: Independent practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Independent practice of sitting balance as an addition to standard physiotherapy treatment based on the Bobath Approach for four weeks.
Study: 12194618
Drug: Standard physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physiotherapy treatment based on the Bobath Approach (control group).
Study: 2088195
Drug: Ciprofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (200 mg) + Clindamycin (600 mg)
Study: 2088195
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg) + Clindamycin (600 mg)
Study: 2088195
Drug: Fleroxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin (400 mg) + Clindamycin (600 mg)
Study: 2088195
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg) + Metronidazole (500 mg)
Study: 2088195
Drug: Enoxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin (400 mg) + Metronidazole (400 mg)
Study: 2088195
Drug: Fleroxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin (400 mg) + Metronidazole (400 mg)
Study: 2088195
Drug: Fleroxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin (400 mg) + Ornidazole (500 mg)
Study: 520100
Drug: Aspirin (3600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (3600 mg/d)
Study: 520100
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg/d)
Study: 520100
Drug: Indomethacin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (150 mg/d)
Study: 520100
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg/d)
Study: 520100
Drug: Naproxen (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (750 mg/d)
Study: 520100
Drug: Ibuprofen (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1600 mg/d)
Study: 520100
Drug: Ibuprofen (2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (2400 mg/d)
Study: 22154397
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training (ER, n = 10)
Study: 20885293
Drug: Sugammadex (0.22
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (0.22 mg/kg)
Study: 20885293
Drug: Neostigmine (34
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (34 μg/kg)
Study: 17508624
Drug: Oral-B Pulsar
Normalized name: Oral-B Pulsar 3D White Luxe Pulsar Toothbrush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B Pulsar (PUL)
Study: 17508624
Drug: Oral-B Advantage
Normalized name: Advantage Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B Advantage Plus (AP)
Study: 17508624
Drug: Oral-B CrossAction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B CrossAction (CA)
Study: 17508624
Drug: Oral-B CrossAction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B CrossAction Power (CAP)
Study: 10077031
Drug: OptiMARK (gadoversetamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: OptiMARK (gadoversetamide injection) 0.1 mmol/kg
Study: 10077031
Drug: OptiMARK (gadoversetamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: OptiMARK (gadoversetamide injection) 0.3 mmol/kg
Study: 10077031
Drug: OptiMARK (gadoversetamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: OptiMARK (gadoversetamide injection) 0.5 mmol/kg
Study: 7324833
Drug: oxycodone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxycodone (10 mg)
Study: 30777086
Drug: AZD7594 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7594 800 μg
Study: 30777086
Drug: AZD7594 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7594 250 μg
Study: 30777086
Drug: AZD7594 58
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7594 58 μg
Study: 30777086
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of AZD7594
Study: 29103052
Drug: Isradipine as
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine as a disease modifying agent for PD
Study: 25827292
Drug: Early enteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early enteral feeding (intraoperative nasojejunal tube placement and enteral feeding until adequate oral intake could be maintained)
Study: 21059817
Drug: Methylphenidate (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0, 10, 20, and 40 mg)
Study: 17530638
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no bosentan treatment)
Study: 15238592
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein containing 99 mg of isoflavones (25.6 g daily for 12 months)
Study: 9489580
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapies
Study: 8194505
Drug: Zinc with
Normalized name: Zinc with Vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc with 600 mg elemental calcium as calcium carbonate
Study: 8194505
Drug: Zinc with
Normalized name: Zinc with Vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc with 600 mg elemental calcium as calcium citrate
Study: 3651528
Drug: RS 86
Normalized name: (RS)-bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RS 86 (oral, long-acting muscarinic agonist)
Study: 27900813
Drug: 2% sevoflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% sevoflurane at 1 l·min‐1 fresh gas flow [O2 : N2 O = 50 : 50]
Study: 27900813
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow reduced to 0.5 l·min‐1 [O2 : N2 O = 50 : 50] (control group)
Study: 25840693
Drug: Ipilimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (10 mg/kg, intravenous infusions every 3 weeks for four doses, then every 3 months for up to 3 years)
Study: 16776756
Drug: ProFile .04
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProFile .04 taper rotary instruments
Study: 9375949
Drug: Metoprolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (15 mg IV divided into 3 injections, then 200 mg orally daily for 3 months)
Study: 1492579
Drug: Progesterone solution
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone solution in almond oil, 2 mg/0.1 ml (total dose approximately 11 mg)
Study: 1492579
Drug: Progesterone solution
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone solution in dimethicone, 5 mg/0.1 ml (total dose approximately 28 mg)
Study: 30006308
Drug: Questions about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Questions about symptoms and hypoglycaemia treatment
Study: 23778343
Drug: Saint John's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saint John's wort (300 mg daily for three months)
Study: 18791717
Drug: Tocosol Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocosol Paclitaxel (175 mg/m², 15 min infusion)
Study: 18791717
Drug: Taxol (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxol (175 mg/m², 3 h infusion)
Study: 17348991
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% N-acetyl glucosamine (NAG)
Study: 17348991
Drug: Topical combination
Normalized name: soap TOPICAL COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical combination of 2% N-acetyl glucosamine (NAG) with 4% niacinamide
Study: 11518072
Drug: Jarsin 300
Normalized name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [ILIA SUPER SERUM SKIN TINT (ST16.5 JARDIN)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jarsin 300 (9 tablets)